Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treat
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram
GS2-01: "Overall survival subgroup analysis by metastatic site from the phase3 MONALEESA-2..." - YouTube
Download Poster: Overall Survival with Kisqali® plus Endocrine Therapy in Patients with Advanced Breast Cancer with Visceral Metastases 6
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting - The ASCO Post
MONALEESA-3: Updated Survival
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer | NEJM
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3 | Journal of Clinical Oncology
Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer - The ASCO Post
Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm - Boyle - 2018 - Asia-Pacific Journal of Clinical Oncology - Wiley Online Library
ESMO-BC 2022: Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) +
Efficacy of KISQALI® (ribociclib) + Fulvestrant in 1L Postmenopausal | HCP
Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer | npj Breast Cancer
![ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).](https://larvolclin.s3.us-west-2.amazonaws.com/resize_162308040295527161060be3dd24570a.png "ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).")
ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
Kisqali extends survival by 1 year in advanced breast cancer < Pharma < Article - KBR
